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Introduction
Structure-based drug design has established itself as a 
fundamental and essential approach in most drug-de-
velopment programs based on its continuing success in 
delivering novel drugs to clinical trials [1–8]. The de-
sign of drugs using structural information is an iterative 
procedure where each pass of the design cycle requires 
obtaining a new structure for the lead compound(s) 
complexed with the protein of interest [6, 9–11]. This 
process is challenging in itself when applied to a single 
protein target but, in the realm of structural genomics, 
structure-based drug design becomes a formidable task 
with the defi nite possibility of being overwhelmed by 
the sheer magnitude of available structures [12]. Never-
theless, NMR [13, 14], X-ray [15, 16] and high-through-
put screening (HTS) [17–22] are rising to the challenge 
of integrating structural genomics into a structure-based 
drug design program. In the ongoing evolution of struc-
tural genomics, NMR, X-ray and HTS will all continue 
to play critical and complementary roles. 
Initiating the structure-based drug design cycle has 
traditionally depended on HTS for providing fi rst-gen-
eration lead-compounds to obtain co-structures with the 
protein target of interest. Similarly, X-ray crystallogra-
phy has historically been a major source for obtaining 
three-dimensional structures of protein–ligand com-
plexes for the iterative drug design cycle [23]. The use 
of NMR for the structure elucidation of protein-ligand 
complexes is a relatively recent addition to the struc-
ture-based drug design approach [24] where a number 
of barriers exist that have sometimes limited its applica-
tion. Utilizing current state-of-the art methodologies, X-
ray crystallography is generally more effi cient in solving 
protein structures than NMR, where NMR is also limit-
ed to relatively low-molecular-weight proteins. Specif-
ically, NMR requires extensive isotope labeling of the 
protein and may take six months to a year using standard 
methodology to determine a high-resolution structure 
for proteins <40 kDa. Conversely, X-ray crystallogra-
phy routinely solves protein–ligand structures in weeks 
to months and in some cases as fast as a few days. 
In spite of these limitations, the role of NMR in 
structure-based drug programs is continually expanding, 
where NMR is routinely being adapted to complement 
inherent limitations in X-ray crystallography and HTS. 
Specifi cally, NMR is routinely being used to identify 
and evaluate chemical leads [24–28]. One reason for this 
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development arises from the fact that results from HTS 
assays do not provide mechanistic information. The data 
obtained from an HTS screen does not readily establish 
if the observed activity results from the compound actu-
ally binding and inhibiting the protein target of interest. 
It is equally likely that the inactivation observed in an 
HTS screen is through another component of the assay 
or by some other physical means such as precipitation. 
Furthermore, the effi cient and potentially rapid structure 
determination by X-ray is dependent on the prior identi-
fi cation of well-behaved stoichiometric binders. 
Recent advances in probe technology [27], soft-
ware development [29] and NMR methodology [14, 
30–32] show exciting promise in signifi cantly reduc-
ing the time requirement to determine a protein struc-
ture by NMR while simultaneously increasing the mo-
lecular-weight range of proteins amenable to NMR. 
Nevertheless, the present application of current NMR 
methodology in novel ways provides a plethora of in-
formation that is benefi cial to the structure-design pro-
cess. Based on the current state of NMR technology, a 
role for NMR in structural genomics may be described 
through a series of ‘low resolution’ alternatives in com-
bination with traditional high-resolution solution struc-
ture determination (Figure 1). 
NMR Screening
An unfortunate reality of screening large libraries of 
compounds in traditional HTS assays is that many of the 
identifi ed ‘hits’ exhibit undesirable mechanisms of ac-
tivity or poor physical properties. These poor proper-
ties of the compound may include insolubility, impuri-
ties, aggregation, instability and non-specifi c binding. 
As a result, depending on the nature of the assay and 
the protein target, only a small percentage of the iden-
tifi ed hits actually bind the protein target of interest in 
a desirable manner. From experience, there is a high-
correlation between ‘good’ behavior by a small-molec-
ular-weight compound in the NMR and future success 
in obtaining a co-structure. ‘Good’ behavior is charac-
terized by compounds that exhibit stoichiometric bind-
ing to the target protein without solubility or aggrega-
tion issues and/or any observable detrimental impact on 
the protein itself (precipitation, denaturation, etc.). The 
1D NMR structure of the free compound readily indi-
cates the relative aqueous solubility and stability of the 
compound, the compound’s tendency to form high-mo-
lecular-weight aggregates or micelle-like structures and, 
in addition, the accuracy of the structure. 
Similar, a variety of NMR techniques may be uti-
lized to verify binding, stoichiometry, and identifi ca-
tion of the binding site on the protein [26, 27]. These 
include the ‘SAR by NMR’ [25] and SHAPES [33] ap-
proaches of screening libraries using NMR. ‘SAR by 
NMR’ identifi es binders from chemical shift pertur-
bations in 2D 1H-15N HSQC spectra. By mapping the 
chemical shift changes on the surface of the protein, the 
binding site may be identifi ed which permits chemical-
ly linking compounds that bind proximal to each oth-
er. The SHAPES methodology utilizes a small-diverse 
library (< 200) derived from known drug structures 
where binding to a target protein is identifi ed from 1D-
Figure 1 Current application of low-resolution NMR methodologies in a structure-based drug design program that are applicable to struc-
tural genomics. 
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line-broadening or 2D-transfer NOEs experiments. Pos-
itive ‘hits’ are used as starting points for ligand design 
by using the compounds as the basis for structure-based 
searches of compound databases, directing the design 
of compound libraries for HTS assays or for guiding the 
synthesis of combinatorial libraries. 
In general, initial chemical leads tend to be weak 
binders where the affi nity is optimized through com-
bined application of modeling, medicinal chemistry and 
structural information. The upper KD limit (~ μmol/L) 
for weak binders identifi ed in standard HTS assays is 
usually defi ned by practical issues that affect protein and 
compound concentrations (solubility, availability, activi-
ty, etc.). Conversely, the NMR screening methodologies 
are equally suited for identifying both weak and tight 
binders (KD ~ nmol/L to mmol/L), depending on the na-
ture of the experiment. NMR-based screens may readily 
identify very weak binders that may be missed in tradi-
tional HTS assays. Thus, NMR analysis provides critical 
information to evaluate the utility of the compound prior 
to initiating a structural effort (Figure 2). 
Given the benefi cial and versatile utility of NMR 
to evaluate chemical leads, NMR would appear to be 
a useful alternative to standard HTS techniques to 
screen small molecules for their ability to bind pro-
tein targets of interest [24–27]. Unfortunately, there 
are a number of disadvantages associated with a pure-
ly NMR-based screening approach. Since NMR is a 
relatively insensitive analytical technique, large quan-
tities of protein (100 mg to > 1 g) are required for 
a typical screen. Additionally, the NMR experiments 
used in a screening effort generally require long ac-
quisition times (> 10 min) and isotope enrichment of 
the protein (2H, 13C, 15N). 
Concurrent with NMR screening efforts, a number of 
methods using only mass spectrometric detection have 
been proposed for the screening of drug candidates by 
evaluating non-covalent complexes between the ligand 
and a targeted protein [34–36]. Mass spectrometry (MS)-
based assays have some advantages compared with the 
NMR screening approaches, particularly in the signifi -
cant increase in sensitivity (femtomoles) and speed (~ 1 
min/sample). Also, MS screens eliminate the need to de-
convolute since the MW of the compound can be used 
as a molecular tag for identifi cation of ‘hits.’ Converse-
ly, there are signifi cant disadvantages with MS-based 
assays relative to the NMR methods. The main disad-
vantage of MS screens is the inability of the method to 
discriminate between specifi c and non-specifi c binding 
of the drug to the targeted protein. Also, because of the 
increase in sensitivity, MS screen is more likely to iden-
tify weak non-specifi c binders. Additionally, screen-
ing by MS does not provide any direct information re-
garding the binding site of the ligand or the structure 
of the protein : ligand complex, which are fundamental 
strengths of NMR-based screens. 
Based on the observation that NMR and MS screen-
ing efforts are complementary to each other, an MS/
NMR screen was developed and previously described 
that takes advantage of and combines the inherent 
strengths of size-exclusion gel chromatography, mass 
spectrometry and NMR to identify bound complex-
es in a relatively universal high-throughput screen-
ing approach [28]. A diagram of the MS/NMR screen 
utilizing MMP-1 binding data is depicted in Figure 3. 
Briefl y, size-exclusion gel chromatography is used to 
separate successful protein–ligand complexes from 
compounds that don’t bind the protein target. This step 
of the assay may utilize mixtures where unique molec-
ular weights for each compound in the mixture can be 
used as a molecular tag for deconvolution. Mass spec-
trometry is then used as a detector to analyze the elu-
ent from the size-exclusion gel chromatography for the 
presence of a MW corresponding to a small molecule 
in the mixture. The sensitivity of the approach is prob-
ably dependent on the off-rate instead of the KD since 
the gel-fi ltration size exclusion chromatograph occurs 
under non-equilibrium conditions and favors dissocia-
tion of the protein–ligand complex [37, 38]. Also, oth-
er factors such as concentration and loading volume on 
the column will affect the detection limit. Empirically, 
a good signal for binders with IC50s in the ~100 μmol/
L range was observed, suggesting that a 200 μmol/L 
binder should be detectable. Conversely, a compound 
with an IC50 of ~1 mmol/L was not detected, which 
suggests that the upper limit of detection is probably in 
the range of  > 200 μmol/L to 1 mmol/L. 
Positive ‘hits’ from the MS stage are then further 
analyzed for binding by the presence of chemical-shift 
perturbations in a 2D 1H-15N HSQC NMR spectrum. 
Compounds that exhibit chemical shift changes that 
cluster in a biologically relevant region of the protein’s 
surface are then used to determine a costructure with 
the protein target. The MS/NMR assay was successful-
ly used to screen ~ 32,000 compounds against RGS4 
as the target protein where a compound was identifi ed 
that exhibited specifi c binding to RGS4 and inhibited 
the RGS4-Gα interaction [28]. 
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Figure 3 Pictorial fl ow diagram of MS/NMR assay using data from the MMP-1 binding assay. (From reference [28] Copyright 2001 by the 
American Chemical Society.) 
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Homology models based on NMR data
A major proposal of ongoing structural genomic pro-
grams is to limit the high-resolution structure determi-
nation effort to novel protein folds and to utilize ho-
mology modeling to determine the structures of the 
remaining proteins [39, 40]. In traditional homology 
models based on sequence alignment, the accuracy of 
the resulting homology model is strongly dependent on 
the sequence identity between the reference and target 
protein sequence. Typically, when the sequence identi-
ty falls below 30%, the homology models become less 
reliable where the atomic rms difference between the 
homology model and experimental structure may ex-
ceed 3 Å [41, 42]. Since a number of structural homo-
logs have sequence identity signifi cantly below 30%, 
standard homology modeling efforts may be limited. 
NMR may play a key role in this endeavor by incorpo-
rating readily obtainable experimental data in the ho-
mology modeling process [43, 44]. 
The secondary-structure elements present in a pro-
tein are generally identifi ed rapidly by NMR as part 
of a standard sequence assignment procedure [45]. 
The regular secondary structure elements are identi-
fi ed from a qualitative analysis of sequential and in-
ter-strand NOEs, NH exchange rates, 3JHNα coupling 
constants and the 13Cα and 13Cβ secondary chemical 
shifts [46, 47]. The resulting secondary structure can 
then be used to generate a sequence alignment based 
on a correlation between the secondary structure ele-
ments between the target and reference proteins. Ef-
fectively, the NMR data permits a sequence align-
ment based on a higher information content then the 
primary sequence alone. Additional information, such 
as the location of cysteins involved in disulfi de bonds 
and highly conserved residues can be used to aid the 
alignment. The application of NMR-derived struc-
tural information was used to determine a homolo-
gy model for Oncostatin M (Figure 4) [48]. Combin-
ing mutational data with the Oncostatin M homology 
model generated a reasonable representation of the re-
ceptor-binding surface consistent with other interleu-
kins and growth factors. This information provided 
support for the reliability of the Oncostatin M homol-
ogy model. An additional utility of a structure-based 
sequence alignment was illustrated in the functional 
analysis of IL-13 [49] where a model of IL-13 com-
plexed to the IL-4α receptor was generated from the 
IL-13 NMR structure and the IL-4 : IL-4α receptor X-
ray structure. Furthermore, the generation of a homol-
ogy model based on initial NMR information would 
provide a convenient structure as a starting point for 
the complete analysis of the NOE structural informa-
tion and determination of a high-resolution structure. 
NMR structures based on minimal restraints
Currently, the most time-consuming aspect of deter-
mining a protein structure by NMR is the manual in-
terpretation and assignments of thousands of NOE-
based distance restraints. It is well established that the 
relative precision and accuracy of a protein structure 
determined by NMR methodology is inherently de-
pendent on the number and accuracy of the restraints 
used to determine the structure [50]. Clearly indicating 
that the thorough analysis of the NOESY experimental 
data is a crucial component for obtaining a high-qual-
ity NMR structure. The analysis of NOE data is an it-
erative process where an initial structure is used as a 
distance fi lter to aid in deciphering ambiguous NOE 
assignments. Obtaining a reliable initial structure is 
critical to the entire process where a high-quality ho-
mology model (see above) would expedite this pro-
cess. A desirable alternative would be to determine an 
NMR structure of a protein amenable for a structure-
based drug design program while avoiding the tedious 
analysis of NOESY data. Towards this end, a number 
of software approaches have been developed to expe-
dite the NMR structure determination process, includ-
ing ARIA [51], Auto-Structure [52], NOAH/DIAMOD 
[53, 54], and RossettaNMR [55, 56] 
Recently, novel approaches have been established 
that provide a means to obtain structural information in-
dependent of traditional NOEs. Most notable is the mea-
surement of residual dipolar couplings in partially ori-
ented proteins dissolved in lipid bicelle solution [32]. 
Recent efforts have demonstrated that it is possible to 
reproduce the general fold of a protein using minimal 
NOE restraints and residual dipolar couplings where an 
rmsd of < 1 Å between the structures calculated with the 
complete data set and a minimal number of restraints is 
obtainable [57, 58]. Based on this success, a number of 
software programs have been developed in attempts to 
determine protein structures based solely on residual di-
polar coupling constants [44, 56, 59–61]. 
The prior analyses of the utility of residual dipolar 
coupling constants in structure determinations were ex-
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panded to evaluate the utility of a protein structure deter-
mined from minimal restraints in a structure-based drug 
design program. Particularly, would the active site of a 
protein be reasonably reproduced in a structure deter-
mined from minimal restraints such that it would be use-
able in a drug design effort [62]? The overall structure 
and active site of the MMP- 1 : CGS-27023A complex 
was analyzed using a minimal set of NOEs (NH, meth-
yl and aromatic), residual dipolar coupling constants and 
other readily obtainable restraints (chemical shifts, H-
bonds, J-coupling). Comparison of the MMP-1 structure 
calculated with the minimal restraint set with the struc-
ture based on the complete data set reveals similar struc-
tures that maintain the fundamental characteristics of 
the active site. The rmsd for the active-site backbone at-
oms was 0.67 Å where the overall shape and size of the 
S1’ pocket were consistent (Figure 5). More important-
ly, the binding interaction of CGS-27023A in the struc-
ture based on minimal restraints is strikingly similar to 
the structure based on the complete data set. This anal-
ysis indicates that, in lieu of a high-resolution structure, 
an NMR structure based on minimal restraints would be 
a viable starting point to initiate a drug design process. 
Protein–ligand complexes
A fundamental component of the structure-based drug de-
sign protocol is the iterative structure determination pro-
cess. As each new lead candidate is identifi ed, a new 
complex structure is required. Clearly this aspect of the 
process is critically dependent on a very rapid determina-
tion of the protein–ligand complex, where a turn-around 
time of days to weeks is typically required to support the 
drug design effort. This rapid need for protein–ligand 
complexes precludes solving a high-resolution structure 
by standard NMR methodology. In lieu of a high-resolu-
tion structure, a structure of a protein–ligand complex can 
be obtained by augmenting a complete restraint list that 
defi nes a protein structure with intermolecular NOEs ob-
tained between the protein and the new ligand [63, 64]. 
As an example, the solution structure of CL-82198 com-
plexed to MMP-13 was determined using the structural re-
straints from the MMP-13 : WAY-151693 NMR structure 
[65] appended with the intra- and inter-molecular NOEs 
for CL-82198 complexed to MMP-13 obtained from 2D-
12C,12C-fi ltered-NOESY and 3D-13C-fi ltered/13C-edited-
NOESY spectra. The original structural restraints for the 
MMP-13 : WAY- 151693 complex was edited to remove 
the WAY-151693 restraints and MMP-13 intra-molecu-
lar NOEs that were inconsistent with the new MMP-13 : 
Figure 5 Reproduction of the overall structure and active-site of MMP-1 complexed with CGS-27023A using minimal NOE restraints. 
(From reference [62].) (A) Best-fi t superposition of the backbone of MMP-1 structure for residues in active site together with CGS-27023A. 
The active residues displayed are 80–82, 112–115, and 138–140 that play a critical role in MMP-1 activity. MMP-1 : CGS-27023A complex 
calculated with a complete set of restraints is colored green and the structure based on the minimal restraint set is colored red with CGS- 
27023A (magenta) docked in. The S1’ pocket of MMP-1 calculated from a minimal set (B) and a complete set (C) of restraints for MMP-1 
with CGS-27023A docked in for comparison. 
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CL-82198 complex. Essentially, the new intra- and inter-
molecular NOEs for CL-82198 are given precedence in 
defi ning the structure of the active site for MMP-13. The 
utility of the MMP-13 : CL-82198 structure was verifi ed 
by the success of designing a potent and selective inhibi-
tor of MMP-13 (Figure 6). Thus, it is routinely feasible to 
determine a protein–ligand complex structure by NMR in 
a few weeks and with the implementation of cyroprobes 
this time-period may be reduced to a few days [27]. 
Conclusions
Using currently available NMR methodology, it is rou-
tinely feasible to provide rapid structural information 
that will play critical roles in a structure-based drug-de-
sign effort. With the evolving integration of structur-
al genomics into traditional structure-based drug design 
programs, swift structure determination becomes an es-
sential requirement. The NMR approaches demonstrated 
run the full gambit of complexity and cover a range of 
resolution to address a number of key issues that are en-
countered in a drug design program. NMR is now rou-
tinely used to evaluate and identify lead-compounds 
prior to initiating a structural effort. Rapidly obtained 
NMR data may be applied to improve the quality of a 
homology model as part of the structural genomics par-
adigm. Additionally, NMR structures that can be quick-
ly determined from a minimal number of restraints are 
amenable to structure-based design efforts. Furthermore, 
the process of generating iterative protein–ligand com-
plex structures for the design cycle can be accomplished 
swiftly by appending complete NMR restraint informa-
tion that describes a protein structure with the specifi c 
Figure 6 Rapid determination of a protein–ligand complex by NMR by appending a complete restraint data set with ligand specifi c intra- and 
inter-molecular restraints (from [64]). (A) Design scheme showing the fl ow from CL-82198 and WAY-159062 to WAY-170523. (B) Expand-
ed view of the NMR MMP-13 : CL-82198 complex overlayed with the MMP-13 : WAY-152177 model demonstrating approach to forming the 
hybrid inhibitor WAY-170523 where the MMP-13 active site is shown as a grid surface with CL-82198 and WAY-152177 shown as liquorice 
bonds. View is looking at the S1’ pocket. The table lists the observed IC50 and selectivity for the hybrid compound. 
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ligand-based intra- and inter-molecular restraints. Final-
ly, with recent advances in probe technology, software 
development and NMR methodology the time commit-
ment for solving a high-resolution structure by NMR 
will continue to decrease and the molecular-weight lim-
itations for proteins amenable for NMR will continue to 
increase. 
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